丙戊酸镁缓释片联合阿立派唑治疗脑损伤所致精神障碍疗效分析

目的探讨丙戊酸镁缓释片联合阿立派唑治疗脑损伤所致精神障碍患者的临床疗效及安全性。方法将54例脑损伤所致精神障碍患者随机分为合用组和单用组,合用组为丙戊酸镁缓释片合用阿立哌唑片,单用组为单用阿立哌唑片,疗程均为6周。在治疗前和治疗后分别用PANSS评分量表评定其疗效,观察两者的副作用,并以TESS量表评定其不良反应。结果治疗6周末,合用组有效率为92.59%,单用组有效率为70.37%,两组比较差异有显著性(χ2=4.01,P<0.05),合用组治疗2周末起较单用组下降更显著(t=6.79,P<0.01)。两组TESS评分比较差异无显著性(t=1.64,P>0.05)。结论丙戊酸镁缓释片联合阿立哌唑片能显著提高脑损伤所致精神障碍患者的临床疗效,且安全性高,依从性好。

Comparison study of magnesium valprote sustained release tablets with aripiprazole in treatment mental disorders of brain injury patients

ObjectivesTo assess the efficacy and effects of magnesium valprote sustained release tablets with aripiprazole in treatment of mental disorders of brain injury patients.MethodsAccording to hospitalization sequence,54 depressive mental disorders during to brain injury patients were randomly divided into two groups,magnesium valprote sustained release tablets combined with aripiprazole group(combination group)(n=27) and aripiprazole alone(single group(n=27).PANSS was used to assess efficacy.And the side effects were evaluated by TESS.ResultsAt the end of the 6th week,The total effective rate of the combination group was 92.59%,that of the single group was70.37%,(χ2=4.01,P<0.05,)PANSS the former was significantly higher than the latter in between two groups.There was no significant difference between the two groups in TESS(t=1.64,P>0.05).ConclusionMagnesium valprote sustained release tablets with aripiprazole can improve the curative effect in the treatment of mental disorders of brain injury patients,high safety and good compliance.